Marjorie Green

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. pmc Radiation dose escalation for loco-regional recurrence of breast cancer after mastectomy
    Heath D Skinner
    Department of Radiation Oncology, The University of Texas M, d, Anderson Cancer Center, Houston, TX 77030, USA
    Radiat Oncol 8:13. 2013
  2. ncbi request reprint Neoadjuvant chemotherapy for operable breast cancer
    Marjorie Green
    Department of Breast Medical Oncology, The University of Texas, M D Anderson Cancer Center, Houston 77030 4009, USA
    Oncology (Williston Park) 16:871-84, 889; discussion 889-90, 892-4, 897-8. 2002
  3. ncbi request reprint Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks
    Marjorie C Green
    The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 424, Houston, TX 77030, USA
    J Clin Oncol 23:5983-92. 2005
  4. ncbi request reprint Neoadjuvant chemotherapy
    Marjorie C Green
    Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Breast Dis 21:23-31. 2004
  5. ncbi request reprint Adjuvant chemotherapy for breast cancer
    Marjorie C Green
    Department of Breast Medical Oncology, MD Anderson Cancer Center, University of Texas, TX 77030 4009, USA
    Langenbecks Arch Surg 387:109-116. 2002
  6. doi request reprint Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer
    Cornelia Liedtke
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 1439, USA
    J Clin Oncol 26:1275-81. 2008
  7. ncbi request reprint Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response
    Radhika Rajan
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer 100:1365-73. 2004
  8. ncbi request reprint Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy
    W Fraser Symmans
    Department of Pathology, Unit 85, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 25:4414-22. 2007
  9. doi request reprint Short-term biomarker modulation prevention study of anastrozole in women at increased risk for second primary breast cancer
    Banu Arun
    Department of Breast Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA
    Cancer Prev Res (Phila) 5:276-82. 2012
  10. pmc Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer
    Roman Rouzier
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Proc Natl Acad Sci U S A 102:8315-20. 2005

Detail Information

Publications18

  1. pmc Radiation dose escalation for loco-regional recurrence of breast cancer after mastectomy
    Heath D Skinner
    Department of Radiation Oncology, The University of Texas M, d, Anderson Cancer Center, Houston, TX 77030, USA
    Radiat Oncol 8:13. 2013
    ..Radiation is a standard component of treatment for patients with locoregional recurrence (LRR) of breast cancer following mastectomy. The current study reports the results of a 10% radiation dose escalation in these patients...
  2. ncbi request reprint Neoadjuvant chemotherapy for operable breast cancer
    Marjorie Green
    Department of Breast Medical Oncology, The University of Texas, M D Anderson Cancer Center, Houston 77030 4009, USA
    Oncology (Williston Park) 16:871-84, 889; discussion 889-90, 892-4, 897-8. 2002
    ..Nonetheless, evidence from more recent phase III trials and the fact that neoadjuvant chemotherapy is not harmful topatients validate its use in operable breast cancer...
  3. ncbi request reprint Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks
    Marjorie C Green
    The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 424, Houston, TX 77030, USA
    J Clin Oncol 23:5983-92. 2005
    ....
  4. ncbi request reprint Neoadjuvant chemotherapy
    Marjorie C Green
    Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Breast Dis 21:23-31. 2004
  5. ncbi request reprint Adjuvant chemotherapy for breast cancer
    Marjorie C Green
    Department of Breast Medical Oncology, MD Anderson Cancer Center, University of Texas, TX 77030 4009, USA
    Langenbecks Arch Surg 387:109-116. 2002
    ..This article review the background and implementation of the current use of chemotherapy in adjuvant setting...
  6. doi request reprint Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer
    Cornelia Liedtke
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 1439, USA
    J Clin Oncol 26:1275-81. 2008
    ..In this study, we compared response to neoadjuvant chemotherapy and survival between patients with TNBC and non-TNBC...
  7. ncbi request reprint Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response
    Radhika Rajan
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer 100:1365-73. 2004
    ..In the current study, the authors investigated the contribution of assessing tumor cellularity in the pathologic evaluation of response to chemotherapy...
  8. ncbi request reprint Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy
    W Fraser Symmans
    Department of Pathology, Unit 85, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 25:4414-22. 2007
    ..To measure residual disease after neoadjuvant chemotherapy in order to improve the prognostic information that can be obtained from evaluating pathologic response...
  9. doi request reprint Short-term biomarker modulation prevention study of anastrozole in women at increased risk for second primary breast cancer
    Banu Arun
    Department of Breast Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA
    Cancer Prev Res (Phila) 5:276-82. 2012
    ..Anastrozole is currently being studied as a prevention agent in a large phase III trial and our results provide support for continued evaluation of IGFBP-1 as a surrogate endpoint biomarker in prospective breast chemoprevention studies...
  10. pmc Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer
    Roman Rouzier
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Proc Natl Acad Sci U S A 102:8315-20. 2005
    ..Low tau expression may be used as a marker to select patients for paclitaxel therapy. Inhibition of tau function might be exploited as a therapeutic strategy to increase sensitivity to paclitaxel...
  11. ncbi request reprint Accuracy of the combination of mammography and sonography in predicting tumor response in breast cancer patients after neoadjuvant chemotherapy
    Florentia Peintinger
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Ann Surg Oncol 13:1443-9. 2006
    ..Residual tumor size after neoadjuvant chemotherapy is an important consideration in surgical planning. We examined the accuracy of the combination of mammography and sonography in predicting pathologic residual tumor size...
  12. doi request reprint Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes
    Shaheenah Dawood
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 27:220-6. 2009
    ..The goal of this study was to describe the effect of race on pathologic complete response (pCR) rates and survival outcomes in women with triple receptor-negative (TN) breast cancers...
  13. ncbi request reprint Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer
    Aman U Buzdar
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 424, Houston, TX 77030, USA
    J Clin Oncol 23:3676-85. 2005
    ....
  14. ncbi request reprint Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma
    W Fraser Symmans
    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 97:2960-71. 2003
    ..This study compared gene expression profiles derived from fine-needle aspiration biopsy (FNAB) and from core needle biopsy (CBX)...
  15. ncbi request reprint Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study
    Aman U Buzdar
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 13:228-33. 2007
    ..All data were updated through November 2005...
  16. ncbi request reprint Comparison of ductal lavage and random periareolar fine needle aspiration as tissue acquisition methods in early breast cancer prevention trials
    Banu Arun
    Breast Medical Oncology, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 13:4943-8. 2007
    ..The optimum method to retrieve adequate samples and the most accepted method by study participants is not known...
  17. doi request reprint Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers
    Giampaolo Bianchini
    Department of Breast Medical Oncology, Unit 1354, The University of Texas M D Anderson Cancer Center, PO Box 301439, Houston, TX 77230 1439, USA
    J Clin Oncol 28:4316-23. 2010
    ....
  18. doi request reprint Fast dixon-based multisequence and multiplanar MRI for whole-body detection of cancer metastases
    Jingfei Ma
    Department of Imaging Physics, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Magn Reson Imaging 29:1154-62. 2009
    ..To develop and demonstrate the feasibility of multisequence and multiplanar MRI for whole-body cancer detection...